Apurba Bhattacharya is a professor in the Department of Chemistry at TAMUK. He joined TAMUK in fall, 1999. At the end of 2005, he took a leave of absence from TAMUK and served as the Global R&D Head and Senior Vice President) in Dr. Reddy’s Laboratories in India. Dr. Reddy’s is the largest generic pharmaceutical company with R&D and manufacturing spanning all across the world including USA, Europe SE Asia, Mexico and Canada. He provided leadership and strategic direction for the global R&D (consisting of more than 700 Ph.D. Chemists and Engineers) and serve on senior R&D staff that is responsible for ensuring effective and innovative product development. After two and a half years sabbatical he returned to TAMUK in fall 2008. He has over twenty years of experience in Pharmaceutical industry in the areas of drug delivery and drug development (prior to TAMUK) including Merck (8 yrs), Hoechst (8 yrs), Bristol Myers Squibb (2 yrs), and Dr. Reddy’s Laboratories in India (2 yrs). At Merck, he discovered Finasteride or “Prsocar†(a multi-billion dollar drug for enlarged prostate and prostate cancer) and the hair growth drug “Propeciaâ€. At Hoechst, he developed a process for “Cromolyn Sodium†(for asthma), “Gd/Lu Texaphyrin†(agent for MRI imaging agent for photodynamic therapy of cancer) S-ibuprofen (non-streroidal antinflammatory). At Bristol Myers Squibb, as a director of Process R&D, he led the efforts to develop Nucanzole, another important antifungal drug from BMS. At TAMUK he developed a one step synthesis for Tylenol. He has 7 book chapters, 119 referred publications, 50 patents, 168 research presentations in National and International meetings. His students have made 60 research presentations. He is in the Advisory Board of Clinton Foundation HIV/AIDS Initiative (CHAI). He is a Member of the National Academies’ Chemical Sciences Roundtable (CSR), National Academies Committee on Promoting Safe and secure chemical Management in Developing countries; American Chemical Society Green Chemistry Institute (ACS GCI) Pharmaceutical Roundtable and Panel of Drug Evaluators for Current Drugs (CD). (Responsible for the evaluation of drugs, which are being launched worldwide under FDA guidelines). He is a Scientific Process Advisor for several pharmaceutical companies including Daiichi-Sankyo Pharma, Dr. Reddy’s Laboratories, PHARM-ECO A Johnson Matthey Company, Texas Bio Technology, Bristol Myers Squibb Pharmaceutical Co., Boehringer-Ingelheim Pharmaceutical., Johnson & Johnson Pharmaceutical Research & Development., Ambion and National Advisory Committee, Dr. Reddy’s Laboratories, Chembiotek, India, Osmania University, India, Senator Kay Bailey Hutchison’s List of Designated Expert in Environmental Chemistry, Corpus Christi Regional Economic Development Corporation and NIH: SSS-L study section, SBIR/STTR applications in Drug Discovery, Development and Delivery. He served as a Director, NIH Texas Bridges to Doctorate Program.
Other Editorial Board Members
Maria del Carmen Gonzalez-Montelongo
Institute of Biomedicine and Biomedical Innovation of Cadiz
View Profile
Gayathri Acharya
Investigator (Formulation development) in Dermatology TAU at GSK
View Profile
Sushil Kumar Sharma
Sam Higginbottom University of Agriculture, Technology and Sciences (SHIATS)
View Profile
Chat with us on WhatsApp
